ViruCure Therapeutics is a biotech company that is developing an oncolytic-virus-based technology platform, using proprietary strains of Newcastle Disease Virus (NDV), for the targeted treatment of a wide range of cancers.
INITIAL TARGETED THERAPIES FOR THE TREATMENT OF GBM & LUNG CANCER
ViruCure’s robust NADAV platform has already shown the potential to have significant oncolytic effect on a wide range of cancers including Glioblastoma Multiforme (GBM) and lung cancer, which are the two initial target indications to be addressed by ViruCure.
DRAMATIC RESULTS IN PROOF OF CONCEPT TRIAL
In a Phase 1/2 clinical trial on terminal GBM patients, four of twelve patients responded to treatment and one went into complete remission! Studies have also been conducted on metastatic chemo-resistant melanoma in mice and human organ cultures in lung cancer, head and neck, as well as colorectal carcinomas.
THE NADAV TECHNOLOGY PLATFORM
NADAV’s oncolytic effect appears to be a result of both direct destruction of the tumor cells (cell death) and activation of a general anti-tumor immune response. This powerful amplification effect is achieved with very low toxicity because NADAV specifically destroys tumor cells and does not attack normal tissues. Furthermore, since NDV is an avian virus, it has not exhibited any pathological effects or severe illnesses in humans in over forty years of research.
BREAKTHROUGH TREATMENTS
ViruCure believes that NADAV may serve as a breakthrough treatment modality where conventional cancer therapies have shown poor results. Given its broad applicability, the NADAV platform will generate an evergreen pipeline of anti-cancer candidates, some of which ViruCure will bring to market on its own and others through strategic partnerships.
Company Details
- Founded
- -
- Address
- Mezada 8, Bnei Brak,israel 5126203,israel
- in****@****ure.com
- Industry
- Biotechnology
- Website
- virucure.com
- Keywords
- Oncology, Virotherapy, Immunotherapy, Biotechnology, Targeted Therapies, Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Newcastle Disease Virus, Anti-Cancer, Tumors, Oncolytic virus.
- HQ
- Bnei Brak, Israel
Virucure Therapeutics Questions
Virucure Therapeutics's website is virucure.com
Virucure Therapeutics's LinkedIn profile is https://il.linkedin.com/company/virucure-therapeutics
Virucure Therapeutics's industry is
Biotechnology
Virucure Therapeutics's top competitors are
Innocan Pharma,
Neurokaire (Formerly Genetika+),
Rondinx,
Eitan Medical,
Nurexone Biologic (Otcqb:nrxbf) (Tsxv: Nrx) (Fse: J90),
Senseera,
Ir-Med Inc. (Otcqb:irme),
Centarix,
Centa Longevity,
Entera Bio Ltd..
Virucure Therapeutics's support email address is info@Virucure.com
Virucure Therapeutics's categories are Biotechnology
Virucure Therapeutics's founding year is 2016
